The advances in the comprehension of the biological activities and of the impact that mTOR performs in ALL could give a significant contribution to the advancement of new therapeutic strategies, aimed to inhibit mTOR, for ameliorating ALL patient outcomes. The gene discussed is MTOR; the disease is acute lymphoblastic leukemia.